Consensus guidelines

Cardiovascular risk management in patients with rheumatoid arthritis

Cem Gabay1, Nicolas Buchs2, Jean Dudley3, Paul Hasler4, Baris Gencer5, Christian Matter5, Beat Michel5, Johannes von Kempis5, Pascal Zufferey1, François Mach4

1 Division of Rheumatology, University Hospitals of Geneva, Switzerland; 2 Private Practice, Geneva, Switzerland; 3 Division of Rheumatology, HFR Fribourg – Hôpital Cantonal, Fribourg, Switzerland; 4 Division of Rheumatology, Cantonal Hospital Aarau, Switzerland; 5 Division of Cardiology, University Hospitals of Geneva, Switzerland; 6 Division of Cardiology, University Hospital Zurich, Switzerland; 7 Division of Rheumatology, University Hospital Zurich, Switzerland; 8 Division of Rheumatology, University Hospital of Lausanne, Switzerland

Summary

Cardiovascular diseases (CVD) and complications occur prematurely and approximately 1.5 times more frequently in patients with rheumatoid arthritis (RA) compared to the general population. The higher level of CV complications is insufficiently explained by the traditional cardiovascular (CV) risk factors. There is substantial evidence that chronic systemic inflammation contributes to excess CVD in RA and that effective suppression of RA-associated inflammation reduces CV morbidity.

CV risk assessment and management tools were developed many years ago for the general population. A Swiss expert group consisting of cardiologists and rheumatologists has elaborated the following pragmatic guidelines for the management of CV risk in patients with RA. In addition to systematic screening for and reduction of traditional individual CV risk factors based on the national risk score model, the direct link between inflammation and the development of atherosclerosis demands early and effective control of joint and systemic inflammation. Antithrombotic therapy preferably includes methotrexate, a disease modifying antirheumatic drug (DMARD) and, if necessary, tumour necrosis factor-α blockers or other biologics, because they are not only effective in the treatment of RA but might also reduce excess CV events in patients with RA.

Additional treatment should be initiated according to the strategies for lowering circulating lipids and blood pressure as published by the European Society of Cardiology and European Atherosclerosis Society. Pharmacological interventions should be complemented by lifestyle changes.

Key words: cardiovascular risk; rheumatoid arthritis; disease modifying antirheumatic drug; DMARD

Introduction

It is the strong impression of Swiss experts in rheumatology and cardiology that current guidelines, in particular the recent EULAR guidelines [1], are not sufficiently adhered to by specialists and primary care physicians in Switzerland, most likely due to their complexity. Therefore, a Swiss expert group consisting of cardiologists and rheumatologists elaborated user-optimised consensus recommendations on cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA) to address the underappreciated problem of elevated CV risk in RA patients. The ad-hoc expert group convened to discuss and formulate evidence-based consensus opinions without systematic processing of the literature. The aim was to present current “best practice” to primary care physicians and rheumatologists.

Rheumatoid arthritis and risk for cardiovascular disease

Patients with rheumatoid arthritis (RA) have a 50% increased risk for cardiovascular diseases and their complications as compared to the general population. RA is a chronic inflammatory joint disease of unknown aetiology affecting approximately 1% of the general population [2, 3]. As compared to the general population, it is associated with an approximately 50% increase in CV morbidity and mortality, predominantly resulting from accelerated coronary and cerebrovascular atherosclerosis [4, 5, 6, 7]. It has been demonstrated that the prevalence of cardiovascular disease (CVD) in RA patients is increased to an extent comparable to type 2 diabetes mellitus (fig. 1) [8]. The increased incidence of CVD cannot be explained by traditional CV risk factors alone [9, 10]. Various disease-related mechanisms may contribute to premature vascular damage, including an increased synthesis of pro-inflammatory mediators (cytokines, chemokines and adhesion molecules), autoantibodies against endothelial cell components or anti-apolipoprotein lipoprotein, perturbations in T-cell subsets, genetic polymorphisms, hyperhomocysteinaemia, oxidative stress, abnormal vascular repair, and iatrogenic factors [11, 12]. Particularly, the systemic inflammation seems to account for the excess CV risk [13]. There is strong evidence that chronic inflammatory markers...
are independently associated with CV mortality and morbidity in RA patients [14, 15, 16]. Immune dysregulation may also play a role [17]. Moreover, the prevalence of CV risk factors such as dyslipidaemia, diabetes, hypertension, higher Body Mass Index, or impaired physical fitness may be increased in RA patients [18, 19]. Tobacco smoking is associated with both CVD and the development of RA, in particular in genetically susceptible individuals [20].

Although newer disease modifying antirheumatic drugs (DMARDs) and biologic agents have substantially advanced the management of RA and other forms of inflammatory arthritis in the past few years, CVD morbidity and mortality remain significantly increased in patients with RA [21, 22, 23]. But the lack of CV risk assessment tools and evidence-based recommendations developed specifically for RA patients has impeded the implementation of this knowledge in the delivery of clinical care.

**Treatment goals**

Complete clinical remission is the primary treatment goal in the management of RA using early and effective antirheumatic treatment. There is broad consensus among experts that an adequate control of disease activity is a prerequisite to lower the CV risk in RA patients. Long-term clinical remission has become a realistic treatment goal in many patients due to new drug treatment strategies that improve clinical and radiographic outcomes [1, 24]. The current standard for measuring disease activity is the EULAR Disease Activity Score (DAS) and its modified version, the DAS28, including 28 joints [25]. The score is calculated using a formula that incorporates counts of tender and swollen joints (28 joints maximum), an evaluation of the general health by the patient (Visual Analogue Scale 0 to 100), and the erythrocyte sedimentation rate or the C-reactive protein as systemic inflammation markers. Although various definitions of remission have been proposed during the last decade, the most widely used definition in randomised controlled trials has been a DAS28 index with a cut point of <2.6 [26].

Treatments currently used in the management of chronic inflammatory disorders may affect CV risk. Table 1 gives an overview of the current pharmacotherapy with information regarding CV risks associated with each drug class.

---

**Table 1:** Current pharmacotherapy of RA. Effect of different treatment options on cardiovascular risk in RA patients and source of clinical evidence.

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Effect on CV outcomes in RA patients</th>
<th>Clinical evidence (References)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs/COXIBs</td>
<td>? on CVD mortality or HF events</td>
<td>prospective cohort [57, 63]</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>↑ high dose ↓ (low dose) CVD events</td>
<td>cross-sectional [4], prospective cohorts [58, 59], systematic review [60], case-control [71]</td>
</tr>
<tr>
<td>Methotrexate (MTX)</td>
<td>↓ CVD events</td>
<td>cross-sectional [4], prospective cohorts [62, 67], case-control [62], systematic review [64]</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>↓ CVD events</td>
<td>cross-sectional [4], prospective cohort [67]</td>
</tr>
<tr>
<td>Tumor necrosis factor-α blocking agents (TNF-α blockers)</td>
<td>↓ CVD events</td>
<td>cross-sectional [4], prospective cohort [70, 72], meta-analysis [73] and systematic review [74]</td>
</tr>
<tr>
<td>Other biological agents</td>
<td>?</td>
<td></td>
</tr>
</tbody>
</table>

CV = cardiovascular; CVD = cardiovascular disease; HF = heart failure
Cardiovascular risk assessment and estimation of risk in the general population and RA patients

A systematic CV risk-factor screening must be performed in RA patients using the risk score model presented by the Swiss Society of Cardiology (SGK/SSC) and the working group on lipids and atherosclerosis (AGLA) in 2012 (www.agla.ch).

In RA patients, the derived CV risk estimate should subsequently be multiplied by a factor of 1.5, without any restrictions. For this purpose the risk score chart used in Switzerland was modified accordingly (fig. 2). It allows simple and direct assessment of risk score for RA patients.

Assessment of cardiovascular risk should be performed annually in every RA patient.

The major traditional risk factors for CVD are tobacco smoking, elevated blood pressure, elevated serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC), low serum high-density lipoprotein cholesterol (HDL-C), diabetes mellitus, and advancing age. The quantitative relationship between these risk factors and coronary heart disease (CHD) risk has been elucidated by the Framingham Heart Study and other studies [27, 28]. These show that the major risk factors are additive in predictive power. Accordingly, the total risk of a person can be estimated by a summation of the risks imparted by each individual major risk factor. The risk for CHD is assessed with risk charts, and usually the predicted 10-year risk of fatal CVD is determined.
CHD is calculated. The European risk prediction system SCORE (Systemic Coronary Risk Evaluation) has been developed to define the lifestyle, risk factor, and therapeutic targets for CVD prevention. SCORE is representative of typical European populations, and the risk score system has been optimised for coronary prevention in European clinical practice. All risk score charts are presented for TC. However, new data show that HDL-C can substantially contribute to risk estimation if entered as a separate variable as opposed to the TC/HDL-C ratio [29, 30]. For example, HDL-C modifies risk at all levels of risk as estimated from the SCORE cholesterol charts. Therefore, a new risk score chart was developed that includes HDL-C.

The Swiss national guidelines for the prevention of CV events were published in 2005 by the Swiss Society of Cardiology (SGK/SSC) and the working group on lipids and atherosclerosis (AGLA) [31]. In these guidelines, CV risk is stratified into low (<10%), intermediate (10–20%) and high (>20%). Primary prevention with statins and/or antihypertensive agents is only indicated in the general population when this 10-year risk is above 10% (fig. 2).

It is very likely that the use of available CV risk score charts underestimates the CV risk in RA patients, since only traditional risk factors are considered. Nontraditional risk factors such as disease severity and duration significantly increase the CV risk in patients with RA [32, 33, 34]. However, other factors such as rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) positivity are also relevant [35, 36]. Therefore, EU-LAR evidence-based recommendations introduce a multiplication factor 1.5 to adapt the risk score models for RA patients, provided that 2 of the following 3 criteria are fulfilled: Disease duration of over 10 years, RF or anti-CCP positivity, presence of certain extra-articular manifestations [5]. Our Swiss expert group proposes to extend this recommendation to all RA patients in order to simplify management strategy and to acknowledge the fact that most of the epidemiological studies on the risk of CVD in RA did not stratify the patients according to these criteria. In addition to RA, this approach should be implemented in patients with other forms of inflammatory arthritis such as psoriatic arthritis and ankylosing spondylitis, and autoimmune diseases such as systemic lupus erythematosus.

### Intervention strategies on the basis of the cardiovascular risk profile

The same intervention strategies for lowering of LDL-C in the normal population with elevated CV risk should be used in RA patients.

---

Table 2: Intervention strategies for lowering LDL-C levels in patients with RA. For lowering LDL-C levels in RA patients the same strategies as in the normal population with elevated cardiovascular risk should be used. (Reprinted from: Perk J et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635–1701, with permission.)

<table>
<thead>
<tr>
<th>Total CV risk (SCORE) %</th>
<th>LDL-C levels</th>
<th>Intervention strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mg/dl &lt;1.8 mmol/l</td>
<td>No lipid intervention</td>
<td>Lifestyle intervention</td>
</tr>
<tr>
<td>100 mg/dl &lt;4.0 mmol/l</td>
<td>No lipid intervention</td>
<td>Lifestyle intervention, consider drug if uncontrolled</td>
</tr>
<tr>
<td>190 mg/dl &lt;4.9 mmol/l</td>
<td>Lifestyle intervention</td>
<td>Lifestyle intervention, consider drug if uncontrolled</td>
</tr>
</tbody>
</table>

Class/Level

- Class I: Level of evidence A
- Class IIa: Level of evidence B
- Class IIb: Level of evidence C

*In patients with MI, statin therapy should be considered irrespective of LDL-C levels.

**Class of recommendation.

Level of evidence. References to level A: 15–41.

CV = cardiovascular; LDL-C = low-density lipoprotein-cholesterol; MI = myocardial infarction.

---
The LDL-C goals are derived from the total CV risk score, as proposed by ESC/EAS in their guidelines for the management of dyslipidaemia in 2011 (see table 2). The management of arterial hypertension in RA patients is based on the levels of systolic and diastolic blood pressure and the CV risk as described in the ESH/ESC guidelines in 2013. The antihypertensive treatment should be initiated according to the recommendations in table 3, which was modified by the expert group from the corresponding table 2013. The antihypertensive treatment should be initiated in the ESH/ESC guidelines for specific use in RA patients. Based on the levels of systolic and diastolic blood pressure and the CV risk as described in the ESH/ESC guidelines in 2011 (see table 2). In these guidelines, the LDL-C goal is set at <1.8 mmol/l (<70 mg/dl) and/or at least a 50% reduction in LDL-C if the target cannot be reached. In patients at very high risk (e.g., marked elevation of only one risk factor), the LDL-C goal is <2.5 mmol/l (<100 mg/dl); in patients with moderate risk, LDL-C should be lowered to <3 mmol/l (<115 mg/dl) (table 2).

Hypertension should be considered a major risk factor for an array of CV and related diseases [50, 51]. Randomised placebo-controlled trials on blood pressure lowering have demonstrated that antihypertensive treatment translates into significant reductions of CV morbidity and mortality [52]. In 2013, ESH/ESC issued new guidelines on the management of hypertension [53]. Blood pressure is categorised as optimal (systolic blood pressure [SBP] less than 120 mm Hg and diastolic blood pressure [DBP] less than 80 mm Hg), normal (SBP 120–129 mm Hg and/or DBP 80–84 mm Hg), and high-normal (SBP 130–139 mm Hg and/or DBP 85–89 mm Hg), followed by 3 grades of hypertension, and a separate category for isolated systolic hypertension. The presence of RA should be considered a distinct CV risk factor as presented in the modified table of the expert group (table 4).

According to the new ESH/ESC guidelines, initiation of blood pressure lowering therapy should be based on two criteria, i.e., the level of systolic and diastolic pressure (SBP/DBP) and the CV risk. The goal of treat-

---

**Table 3:** Antihypertensive treatment strategies in RA patients. (Modified from Mancia G, et al., Eur Heart J. 2007;28:1462–536, with permission.)

<table>
<thead>
<tr>
<th>Blood pressure (mm Hg)</th>
<th>Other risk factors</th>
<th>RA patients ≤1 other risk factor</th>
<th>RA patients ≥2 other risk factor</th>
<th>Diabtes</th>
<th>Established CV or renal disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBP 80–84</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes and consider drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
</tr>
<tr>
<td>SBP 120–129 or</td>
<td>Immediate drug</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
</tr>
<tr>
<td></td>
<td>treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBP 85–89</td>
<td>Immediate drug</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
</tr>
<tr>
<td>High normal SBP 130–139 or DBP 90–99</td>
<td>Immediate drug</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
</tr>
<tr>
<td>Grade 1 HT SBP 140–159 or DBP 90–99</td>
<td>Immediate drug</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
</tr>
<tr>
<td>Grade 2 HT SBP 160–179 or DBP 100–109</td>
<td>Immediate drug</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
</tr>
<tr>
<td>Grade 3 HT SBP ≥180 or DBP ≥110</td>
<td>Immediate drug</td>
<td>Lifestyle changes</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
<td>Lifestyle changes + Drug treatment</td>
</tr>
</tbody>
</table>

HT, hypertension; OD subclinical organ damage; SBP, systolic blood pressure; DBP, diastolic blood pressure

---

...
ment is to reduce blood pressure to at least below 140/90 mm Hg (SBP/DBP).

Non-pharmacological interventions

Lifestyle changes should be recommended individually according to the presumed effectiveness and feasibility. Smoking cessation is of paramount interest. The new ESC/EAS guidelines for the management of dyslipidaemia issued in 2011 stress that lifestyle interventions, including smoking cessation, healthy diet, moderate exercise and moderate alcohol consumption, should be the first step for managing lipids in all patients [49]. Moderate-intensity physical activity is significantly lower in RA patients compared with matched controls [54], and potentially amenable to change. To decrease LDL-C and TC, reduction in dietary saturated fat and trans-fat, as well as cholesterol itself is necessary. Dietary fibre consumption should be increased. It is also recommended to use food enriched with phytosterols. Finally, the guidelines focus on the considerable importance of body weight and central obesity, as they are one of the main problems in western countries.

Pharmacological interventions

Control of the joint disease remains the principal aim, but not all drugs have this far demonstrated additional CV benefits in this population, an element to take into consideration whenever possible, in particular in the high CV risk patient. Current RA therapy strategies aim at remission with full control of joint and systemic inflammation, a control of the inflammation which is an integral part of the strategy to lower the cardiovascular risk, as suggested in the guidelines of ESC/EAS (2012), EULAR (2010) and ESH/ESC (2013). Classical nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 inhibitors (COXIBs) are very commonly used in the treatment of RA. There is still controversy about the effects of NSAIDs on CV disease and mortality. According to the findings of a meta-analysis, high dose regimens of ibuprofen and diclofenac are associated with an increased risk of CV events, but high doses of naproxen are not associated with such an excess [55]. In another cohort study, this risk appeared to be mediated mainly by the effect of NSAIDs on blood pressure [56] stressing the importance of BP control. Of note, the anti-inflammatory effect of NSAIDs could potentially counteract this risk, as in a cohort study in RA patients, the use of NSAIDs was not associated with excess CVD or mortality from all causes [57]. Corticosteroids are commonly used in rheumatic patients and may influence the CV risk in two competing ways. On one hand their anti-inflammatory and antiproliferative action on vessel walls may be cardioprotective, and on the other they affect blood pressure, insulin resistance, lipid profiles, body weight, platelet activity and fat distribution, especially when used long-term at high doses [58, 59]. High-dose corticosteroid therapy appears to be associated with a dose-dependent CV risk increase in RA patients, while exposure to low doses of corticosteroids for 1–3 years does not [57, 60].

There are several indications that DMARDs can alter CV risk by influencing atherosclerotic processes directly through suppression of inflammation or indirectly by affecting CV risk factors. However, few studies have investigated their effects on the occurrence of CVD in RA patients. Methotrexate (MTX) is a cornerstone of the treatment of RA. It improves the clinical signs of disease activity and slows radiographic progression. Patients with RA who take MTX have lower mortality rates and decreased CV morbidity [4, 61, 62]. In a large cohort study of RA patients MTX was associated with a significant decrease in the rate of acute myocardial infarction [63]. A recent meta-analysis came to the conclusion that MTX use is associated with a reduced risk of CVD events in patients with RA [64].

The sparse available data on leflunomide suggest that, despite the small percentage of RA patients developing hypertension under leflunomide, it may reduce the risk of myocardial infarction, but the results are controversial [4, 65, 66, 67]. Tumour necrosis factor-α blocking agents (TNF-α blockers) are potent inhibitors of inflammation and radiographic progression in RA patients. According to the current Swiss and EULAR RA treatment recommendations, TNF-α blockers should be favoured as first-line biologics [68, 69]. Their role in the prevention of CV events in RA patients is of great interest, a further argument currently favouring their use. Several studies indicate that TNF inhibition might improve endothelial function and be associated with decreased CV morbidity, especially in patients with clinical response to therapy [4, 70, 71, 72]. Two recent meta-analyses support the hypothesis that treatment with anti-TNF agents is associated with a reduced risk of all CV events, myocardial infarction, and cerebrovascular accidents in RA patients [73, 74]. The effects of other biologic agents, including abatacept, rituximab and tocilizumab, on CV morbidity in RA remain to be determined [75].
Cardiovascular therapy

Drug treatment of dyslipidaemia and arterial hypertension is identical to that of patients without RA. Preferred first-line treatments are statins, ACE-inhibitors and angiotensin receptor blockers.

Anti-platelet therapy is only recommended in RA patients with established CV disease.

The ESC/EAS guidelines (2011) and the EULAR evidence-based recommendations (2010) propose that if lipid targets are not met with lifestyle changes alone, statins are the treatment of choice for lowering LDL cholesterol levels [1, 49]. The effects of statins in patients with RA might be of additional benefit, since they possess potential anti-inflammatory properties. The selection of a specific statin should be based on consideration of the extent of LDL cholesterol lowering required and the individual's CV risk. The Trial of Atorvastatin in Rheumatoid Arthritis (TARA) randomised 116 patients with RA in a double-blind placebo-controlled trial to receive 40 mg of atorvastatin or placebo as an adjunct to existing DMARDs [76]. The authors found that statins mediated modest but clinically apparent anti-inflammatory effects with lowering of CRP after six months. This study provides some evidence to use statins to selected RA patients. However, it needs confirmation in a larger population of RA patients with assessment of systemic inflammation, morbidity, longer follow-up, CV risk factors outcome (major cardiovascular events). Cost effectiveness and quality of life issues also need to be taken into account. Combination therapy with a cholesterol absorption inhibitor (ezetimibe) or nicotinic acid (niacin) may be considered if the LDL-C target is not met.

Five classes of drugs are considered appropriate as first-line agents for the treatment of hypertension: diuretics; angiotensin-converting enzyme (ACE) inhibitors; calcium channel blockers (CCBs); angiotensin receptor blockers (ARBs), and beta-blockers. However, the use of beta-blockers in hypertension remains controversial.

The EULAR consensus guidelines recommend the preferential use of ACE-inhibitors and ARBs because of their favourable effect on inflammatory markers and endothelial function in patients with RA [77, 78]. Anti-platelet therapy is recommended for patients with established CV disease [79]. For patients with increased CV risk the benefit is lower [80]. The benefit of anti-platelet therapy in RA patients is therefore doubtful, and has to be weighted with the increased risk of gastro-intestinal events in patients with concomitant NSAIDs.

Funding / potential competing interests: No financial support and no other potential conflict of interest relevant to this article were reported.

References – The full list of references is attached to the online version on www.cardiovascm.ch.

Correspondence: François Mach, MD
Division of Cardiology, University Hospitals of Geneva
Rue Micheli-du-Crest 24
CH-1211 Genève Switzerland
francois.mach@hcuge.ch